Evaluation of Branched-Chain Amino Acids in Children with Autism Spectrum Disorder and Epilepsy.

Researchers studied blood levels of certain amino acids (protein building blocks) in children with autism, comparing those with and without seizures to typically developing children. They found that children with autism had lower levels of these amino acids in their blood, whether they had seizures or not. The study suggests this might help us better understand what causes autism, but more research with larger groups is needed.

This cross-sectional study examined branched-chain amino acid (BCAA) levels in 90 children aged 2-7 years, comparing three groups: ASD with epilepsy (n=30), ASD without epilepsy (n=30), and neurotypical controls (n=30). Researchers measured serum levels of leucine, isoleucine, and valine, and assessed autism severity using CARS. Results showed lower median BCAA levels in both ASD groups compared to controls, regardless of epilepsy status. The study also documented various seizure types in children with ASD and epilepsy.

Authors suggest these metabolic differences may contribute to understanding ASD etiology and support genotype-based categorization, though acknowledge larger studies are needed for more reliable conclusions.

Findings suggest potential metabolic biomarkers for ASD that warrant further investigation. May inform future research into amino acid supplementation or metabolic interventions. Results support need for comprehensive epilepsy screening in ASD populations and consideration of metabolic factors in autism assessment and management.

Small sample size of 30 per group limits generalizability. Cross-sectional design prevents establishing causation. Authors acknowledge need for larger studies. Unclear methodology details regarding BCAA measurement and statistical analyses performed.

Autism spectrum disorder (ASD) and epilepsy run hand-to-hand in their pathophysiology. Epilepsy is not an uncommon finding in patients with ASD. The aim of the present study was to identify the metabolic abnormalities of BCAAs (leucine, isoleucine, and valine) in children with ASD with and without seizures in comparison with neurotypical controls. Also, this study aimed to investigate the presence of epileptiform discharges on electroencephalography (EEG) in ASD patients and to describe the types and frequency of seizures observed.

The study included 90 children aged 2-7 years, 30 of whom were diagnosed with both ASD and epilepsy. The other 30 children were diagnosed as ASD without epilepsy, and a comparable 30 normally developed children served as a control group. The groups were matched by age and gender. All patients were referred to the Autism Disorders Clinic for interviews and examinations.

The Childhood Autism Rating Scale (CARS) was applied to all study participants to assess the degree of autism. The present study results show that all types of seizures may be identified in ASD children. The median serum levels of BCAAs were lower in ASD children with and without epilepsy than in neurotypical controls. This opens the door for discussion about new etiologies and better categorizations of ASD based on genotype and genetic abnormalities detected.

More studies with larger samples are needed to understand ASD better and to more reliable evaluate the association between ASD, EEG changes, seizures, and BCAAs.